George Grunberger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8344875/publications.pdf

Version: 2024-02-01

87 papers	10,368 citations	50276 46 h-index	58581 82 g-index
87 all docs	87 docs citations	87 times ranked	9166 citing authors

#	Article	IF	Citations
1	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
2	American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocrine Practice, 2021, 27, 505-537.	2.1	135
3	Reply to N. Virdi. Endocrine Practice, 2021, 27, 1063.	2.1	0
4	Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study. Diabetes Care, 2020, 43, 37-43.	8.6	168
5	Human regular Uâ€500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study. Diabetes, Obesity and Metabolism, 2020, 22, 434-441.	4.4	28
6	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm â€“ 2020 Executive Summary. Endocrine Practice, 2020, 26, 1196-1224.	2.1	117
7	Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. Diabetes Care, 2020, 43, 2744-2750.	8.6	83
8	Continuous glucose monitoring: Musing on our progress in memory of Dr Andrew Jay Drexler. Journal of Diabetes, 2020, 12, 772-774.	1.8	0
9	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019, 42, 1593-1603.	8.6	2,101
10	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodiumâ€“Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	8.6	249
11	Fred W. Whitehouse, MD, MACP (1926â€“2019). Diabetes Care, 2019, 42, 2167-2170.	8.6	0
12	Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Therapy, 2018, 9, 49-66.	2.5	99
13	American Association of Clinical Endocrinologists And American College of Endocrinology 2018 Position Statement On Integration of Insulin Pumps And Continuous Glucose Monitoring In Patients With Diabetes Mellitus. Endocrine Practice, 2018, 24, 302-308.	2.1	37
14	Dysglycemia-Based Chronic Disease: An American Association of Clinical Endocrinologists Position Statement. Endocrine Practice, 2018, 24, 995-1011.	2.1	63
15	Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care, 2018, 41, 2275-2280.	8.6	396
16	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. Current Diabetes Reports, 2017, 17, 21.	4.2	33
17	Letter to the Editor. Endocrine Practice, 2017, 23, 629-632.	2.1	12
18	American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. Endocrine Practice, 2016, 22, 231-262.	2.1	97

#	Article	IF	Citations
19	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocrine Practice, 2016, 22, 753-762.	2.1	242
20	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm â€“ 2016 EXECUTIVE SUMMARY. Endocrine Practice, 2016, 22, 84-113.	2.1	405
21	Continuous Glucose Monitoring: A Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocrine Practice, 2016, 22, 1008-1021.	2.1	151
22	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes/Metabolism Research and Reviews, 2016, 32, 776-790.	4.0	105
23	Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care, 2016, 39, 2026-2035.	8.6	197
24	American Association of Clinical Endocrinologists and American College of Endocrinology â€“ Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan â€“ 2015 â€” Executive Summary. Endocrine Practice, 2015, 21, 413-437.	2.1	359
25	AACE/ACE Comprehensive Diabetes Management Algorithm 2015. Endocrine Practice, 2015, 21, 438-447.	2.1	189
26	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocrine Practice, 2015, 21, 413-37.	2.1	36
27	American Association of Clinical Endocrinologists and American College of Endocrinology Consensus Conference on Obesity: Building an Evidence Base for Comprehensive Action. Endocrine Practice, 2014, 20, 956-976.	2.1	33
28	Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. European Journal of Clinical Pharmacology, 2014, 70, 1277-1289.	1.9	6
29	Obesity Management: Applying Clinical Trial Data to Clinical Care. Endocrine Practice, 2014, 20, 6-19.	2.1	2
30	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocrine Practice, 2014, 20, 977-989.	2.1	172
31	Response to Comment on Grunberger â€œInsulin Analogsâ€”Are They Worth It? Yes!â€•Diabetes Care 2014;37:1767â€“1770 and Davidson â€œInsulin Analogsâ€”Is There a Compelling Case to Use Them? No!â€•Diabetes Care 2014;37:1771â€“1774. Diabetes Care, 2014, 37, e232-e232.	8.6	0
32	The Traditions and Risks of Fasting for Lipid Profiles in Patients with Diabetes. Postgraduate Medicine, 2014, 126, 98-107.	2.0	14
33	Cardiovascular safety trials: Be careful what you wish for (å¿ƒè¡€ç®¡å®‰å…¨æ€§ç©¶ï¼šå¿ƒä½è®¸ç‚„æ„¿). Journal of Diabetes	1.8	2
34	Insulin Analogsâ€”Are They Worth It? Yes!. Diabetes Care, 2014, 37, 1767-1770.	8.6	65
35	Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. Endocrine Practice, 2014, 20, 463-489.	2.1	140
36	Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptineâ€‹<scp>QR</scp> (2åž‹ç³–å°¿ç—…æ²»ç——æ–°è•ï¼šç¬¬1éƒ¨åˆ†.æ™®å…°æž—è,½ä¸Žæº´ésüºâ€QR). Journal of Diabetes,	1.8	29

#	Article	IF	Citations
37	American Association of Clinical Endocrinologistsâ€™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocrine Practice, 2013, 19, 1-48.	2.1	132
38	Will PPAR-Î³ agonist therapy still have a role in diabetes management in 2013?. Diabetes Management, 2013, 3, 41-51.	0.5	1
39	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (æ–°åž‹2åž‹ç³–å°¿ç—…è¯ç‰©ï¼šç¬¬2éƒ¨åˆ†. 2013å¹´ä¸ºåºŠä¾›Šé'ˆå¯¹è‚ä¿ƒèƒ°å²›ç´ ç¼ºé™·çš„æ	1.8	8
40	Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin. Postgraduate Medicine, 2013, 125, 79-90.	2.0	8
41	Enhancing insulin-use safety in hospitals: Practical recommendations from an ASHP Foundation expert consensus panel. American Journal of Health-System Pharmacy, 2013, 70, 1404-1413.	1.0	95
42	Diabetes and Cancerâ€"An AACE/ACE Consensus Statement. Endocrine Practice, 2013, 19, 675-693.	2.1	78
43	Aace Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice, 2013, 19, 327-336.	2.1	318
44	Quo vadisnateglinide? Ten-year perspective. Expert Opinion on Pharmacotherapy, 2011, 12, 2097-2106.	1.8	1
45	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan: Executive Summary. Endocrine Practice, 2011, 17, 287-302.	2.1	80
46	Do we need a fasting lipid profile to assess cardiovascular risk?. Journal of Diabetes, 2011, 3, 172-173.	1.8	5
47	Statement by the American Association of Clinical Endocrinologists Consensus Panel on Insulin Pump Management. Endocrine Practice, 2010, 16, 746-762.	2.1	53
48	Statement by the American Association of Clinical Endocrinologists Consensus Panel on Continuous Glucose Monitoring. Endocrine Practice, 2010, 16, 730-745.	2.1	78
49	Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocrine Practice, 2009, 15, 540-559.	2.1	805
50	Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemiaâ€"When Do the Risks of Diabetes Begin? A Consensus Statement From the American College of Endocrinology and the American Association of Clinical Endocrinologists*. Endocrine Practice, 2008, 14, 933-946.	2.1	187
51	Abnormalities of Vitamin D and Calcium Metabolism after Surgical Treatment of Morbid Obesity: A Study of 136 Patients. Endocrine Practice, 2007, 13, 131-136.	2.1	23
52	Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus. Endocrine Practice, 2007, 13, 260-268.	2.1	71
53	The benefits of early intervention in obese diabetic patients with FBCxâ„¢ â€" a new dietary fibre. Diabetes/Metabolism Research and Reviews, 2007, 23, 56-62.	4.0	69
54	Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochemical and Biophysical Research Communications, 2006, 350, 437-443.	2.1	109

#	Article	IF	Citations
55	Effect of a Peroxisome Proliferator-Activated Receptor-Â Agonist on Myocardial Blood Flow in Type 2 Diabetes. Diabetes Care, 2005, 28, 1145-1150.	8.6	26
56	The C-peptide Signaling. Experimental Diabesity Research, 2004, 5, 25-36.	1.0	26
57	Type 1 Diabetic Neuropathy and C-peptide. Experimental Diabesity Research, 2004, 5, 65-77.	1.0	42
58	Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. Journal of the American College of Cardiology, 2003, 41, 1387-1393.	2.8	426
59	Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control. Diabetes Care, 2003, 26, 1685-1690.	8.6	37
60	Improved Insulin Sensitivity and Resistance to Weight Gain in Mice Null for the Ahsg Gene. Diabetes, 2002, 51, 2450-2458.	0.6	320
61	Plasma Î±2-HS glycoprotein concentrations in patients with acute myocardial infarction quantified by a modified ELISA. Clinica Chimica Acta, 2002, 319, 27-34.	1.1	22
62	Hippocampal neuronal apoptosis in type 1 diabetes. Brain Research, 2002, 946, 221-231.	2.2	282
63	Coronary vascular dysfunction in premenopausal women with diabetes mellitus. American Heart Journal, 2002, 144, 711-8.	2.7	13
64	C-Peptide Attenuates Protein Tyrosine Phosphatase Activity and Enhances Glycogen Synthesis in L6 Myoblasts. Biochemical and Biophysical Research Communications, 2001, 280, 615-619.	2.1	52
65	Genetic Mapping and Functional Studies of a Natural Inhibitor of the Insulin Receptor Tyrosine Kinase: The Mouse Ortholog of HumanÎ±2-HS Glycoprotein. International Journal of Experimental Diabetes Research, 2000, 1, 249-263.	1.1	15
66	Effects of Autonomic Neuropathy on Coronary Blood Flow in Patients With Diabetes Mellitus. Circulation, 1999, 100, 813-819.	1.6	230
67	The Reliability of the Diabetes Care Profile for African Americans. Evaluation and the Health Professions, 1998, 21, 52-65.	1.9	54
68	Â2-Heremans Schmid Glycoprotein Inhibits Insulin-Stimulated Elk-1 Phosphorylation, But Not Glucose Transport, in Rat Adipose Cells. Endocrinology, 1998, 139, 4147-4154.	2.8	3
69	Differences in the Impact of Dietary Restrictions on African Americans and Caucasians With NIDDM. The Diabetes Educator, 1997, 23, 41-47.	2.5	32
70	Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sciences, 1997, 61, 1583-1592.	4.3	56
71	Recombinant human Î±2-HS glycoprotein inhibits insulin-stimulated mitogenic pathway without affecting metabolic signalling in Chinese hamster Ovary cells overexpressing the human insulin receptor. Cellular Signalling, 1996, 8, 567-573.	3.6	22
72	Diabetes and Related Metabolic Risk Factors Among Arab Americans. Annals of Pharmacotherapy, 1995, 29, 573-576.	1.9	25

#	Article	IF	Citations
73	Continuous versus Intermittent Sulphonylurea Therapy in Non-Insulin-Dependent Diabetes Mellitus. Drug Safety, 1993, 9, 249-253.	3.2	8
74	Functional characterization of insulin and IGF-I receptors in chicken lens epithelial and fiber cells. Current Eye Research, 1992, 11, 1137-1145.	1.5	36
75	Diacylglycerols modulate phosphorylation of the insulin receptor from human mononuclear cells. FEBS Journal, 1990, 187, 191-198.	0.2	11
76	High-fat feeding induces tissue-specific alteration in proportion of activated insulin receptors in rats. European Journal of Endocrinology, 1990, 122, 361-368.	3.7	34
77	Effects of food restriction and insulin treatment on (Ca2+ + Mg2+)-ATPase response to insulin in kidney basolateral membranes of noninsulin-dependent diabetic rats. Metabolism: Clinical and Experimental, 1990, 39, 25-33.	3.4	22
78	Factitious Hypoglycemia Due to Surreptitious Administration of Insulin. Annals of Internal Medicine, 1988, 108, 252.	3.9	90
79	Use of tyrosine-containing polymers to characterize the substrate specificity of insulin and other hormone-stimulated tyrosine kinases. FEBS Journal, 1985, 148, 177-182.	0.2	87
80	Tyrosine Kinase Activity of the Insulin Receptor of Patients with Type A Extreme Insulin Resistance: Studies with Circulating Mononuclear Cells and Cultured Lymphocytes. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 1152-1158.	3.6	73
81	Insulin-like growth factor-I (IGF-I) stimulates tyrosine kinase activity in purified receptors from a rat liver cell line. Biochemical and Biophysical Research Communications, 1984, 119, 6-13.	2.1	92
82	The insulin-stimulated receptor kinase is a tyrosine-specific casein kinase. FEBS Journal, 1983, 137, 631-637.	0.2	29
83	11 Insulin receptors in normal and disease states. Clinics in Endocrinology and Metabolism, 1983, 12, 191-219.	1.6	44
84	Protein kinase activity of the insulin receptor in human circulating and cultured mononuclear cells. Biochemical and Biophysical Research Communications, 1983, 115, 560-566.	2.1	52
85	Insulin stimulates phosphorylation of serine residues in soluble insulin receptors. Biochemical and Biophysical Research Communications, 1983, 116, 1129-1135.	2.1	54
86	Hypoglycemia Associated with Antibodies to the Insulin Receptor. New England Journal of Medicine, 1982, 307, 1422-1426.	27.0	144
87	Stimulating Results Signal a New Treatment Option for People Living With Painful Diabetic Neuropathy. Journal of Diabetes Science and Technology, 0, , 193229682210995.	2.2	0